NK Cell enriched-DLI only + NK-DLI + DUK-CPG-001
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloid Malignancies
Conditions
Myeloid Malignancies, Lymphoid Malignancies
Trial Timeline
Jun 8, 2016 → Oct 1, 2024
NCT ID
NCT02452697About NK Cell enriched-DLI only + NK-DLI + DUK-CPG-001
NK Cell enriched-DLI only + NK-DLI + DUK-CPG-001 is a phase 2 stage product being developed by Agilent Technologies for Myeloid Malignancies. The current trial status is unknown. This product is registered under clinical trial identifier NCT02452697. Target conditions include Myeloid Malignancies, Lymphoid Malignancies.
What happened to similar drugs?
10 of 20 similar drugs in Myeloid Malignancies were approved
Approved (10) Terminated (4) Active (8)
Hype Score Breakdown
Clinical
12
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02452697 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Myeloid Malignancies